The Next Stock You Should Consider: GlaxoSmithKline plc (ADR) (GSK)

Some of the best-performing stocks over the past several decades boast long histories of paying dividends to shareholders.  Moreover, if these stocks sell for an apparent discount to their intrinsic values, they might deserve a place in your portfolio. In my opinion, GlaxoSmithKline plc (ADR) (NYSE:GSK) offers both great dividend growth and impressive value. Here’s why you may want to give this notable drugmaker a closer look.

Company Performance in Review

Glaxo is a UK-based, $109 billion pharmaceutical company with a broad array of products.  The company operates through three segments:  Pharmaceuticals, Vaccines, and Consumer Healthcare.  Pharmaceutical products make up the bulk of Glaxo’s business, comprising 68% of the company’s sales.  The Vaccines and Consumer Healthcare groups account for 13% and 19% of sales, respectively.  Glaxo’s business is spread across the world.  The United States provides the most business for the company, but Glaxo derives 68% of its sales from outside the U.S.

GlaxoSmithKline plc (ADR) (NYSE:GSK)Glaxo’s 2012 results were challenged by the continued economic struggles in Europe.  The company reported revenues declined 1% on a constant currency basis in 2012 as compared to the prior year, and full-year earnings per share of $2.91.  While these results aren’t exactly reasons to jump for joy, Glaxo’s sales held up much better than its peers Eli Lilly & Co. (NYSE:LLY) and Pfizer Inc. NYSE:PFE).

Going forward, Glaxo’s growth will be fueled by continued emerging market expansion.  The company plans to continue building its emerging market segment to capitalize on growth in the developing international economies.  This will be accomplished through a combination of organic investment as well as targeted bolt-on acquisitions.

Pfizer’s Pipeline Uncertainties

Pfizer announced solid full-year 2012 results.  The company’s reported diluted earnings per share came in at $1.94.  While the company is currently trading for a reasonable 14 times these earnings, full-year 2012 revenues declined 10%. Management blamed the loss of Lipitor for the bulk of the decline.

You might be concerned about Pfizer losing Lipitor, and for good reason.  Lipitor accounted for $9.6 billion in sales for Pfizer in 2011, almost as much as the company’s next three best-selling products combined. The company will have to allocate significant resources if it wants to replace these lost sales, which will take a toll on the company’s bottom line going forward.  Indeed, Pfizer is forecasting reported diluted earnings per share to be in a range of $1.50 to $1.65 for fiscal year 2013.  As a result, the company is trading for more than 17 times the midpoint of its guided 2013 range.

Glaxo doesn’t have the same level of risk associated with its product pipeline.  Although Glaxo’s Pharmaceuticals and Vaccines segment accounts for more than 60% of its sales, no one therapeutic area within that segment accounts for more than a third of its sales.  Plainly stated, the company isn’t as reliant on one blockbuster drug as Pfizer was with Lipitor.

Eli Lilly’s Stalled Dividend

Meanwhile, Eli Lilly reported full-year 2012 revenues declined 7% year over year and earnings of $3.66 per share.  Consequently, the stock now trades for a modest 15 times trailing earnings.  While Eli Lilly’s share price has performed very well recently, increasing more than 20% in 2012, the company hasn’t provided investors with a dividend increase in almost three years.  Because its stock price has risen so much over the last couple years, the yield is now down to 3.5% at recent prices.  Going forward, management hasn’t provided guidance as to when the company will resume increasing its payout.

As opposed to Lilly’s inability to raise its dividend, Glaxo’s management remains steadfast in their commitment to increasing its payout. The company declared a fourth-quarter dividend higher than its quarterly payout last year.  Glaxo’s four quarterly dividends in 2012 amounted to 74 pence versus 70 pence in 2011, an increase of more than 5% year over year.  Since Glaxo’s stock price leveled off (the stock actually ended 2012 down slightly), new investors will enjoy a yield of more than 5% annualized.

The Foolish Bottom Line

Glaxo doesn’t have the pipeline problems that Pfizer has and also has a more shareholder-friendly dividend policy than Eli Lilly.  While both Eli Lilly and Pfizer had great runs last year, their dividend yields now pale in comparison to Glaxo’s 5% yield.

Pharmaceutical companies like Glaxo provide products that customers can’t go without for very long.  In addition, the company offers an industry (and market) beating dividend yield.  To top it all off, the stock is trading for valuation multiples more attractive than the S&P 500.  The company has all the makings of a highly rewarding long-term holding.  Glaxo and its juicy dividend yield belong in many investors’ portfolios.

The article The Next Stock You Should Consider originally appeared on Fool.com and is written by Robert Ciura.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!